Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451851 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
A Phase 3 study of Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT03451851: Active Phase 3 study of Psoriasis, sponsored by Janssen Research & Development.
NCT03451851 is a Phase 3 study of Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 120 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451851, a Phase 3 study of Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Primary Outcome
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright
Conditions Studied
Interventions
- DRUG Guselkumab
- DRUG Etanercept
- DRUG Placebo for guselkumab
Study Locations (20)
Other
- Eastern Health Research - Box Hill
- Royal North Shore Hospital - St Leonards
- Veracity Clinical Research - Woolloongabba
- Cliniques Universitaires Saint Luc - Brussels
- Universitair Ziekenhuis Gent - Ghent
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman - Liège
- Universitatsklinikum Bonn - Bonn
California
- Stanford University - Palo Alto
- University of California, San Diego - San Diego
Illinois
- Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital - Chicago
- Arlington Dermatology - Rolling Meadows
Texas
- Arlington Center for Dermatology - Arlington
- Dell Children's Medical Center of Central Texas - Austin
Alberta
- Kirk Barber Reseach Inc. - Calgary
- Dermatology Research Institute Inc - Calgary
Georgia
- Dermatologic Surgery Specialists - Macon
New Jersey
- Windsor Dermatology - East Windsor
New York
- Mt. Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2026-12-18 |
| Phase | Phase 3 |
What the registry record for NCT03451851 still lists
NCT03451851 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Guselkumab is the first listed.
NCT03451851 names 20 study sites across 10 states, led by Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03451851 about?
NCT03451851 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants". The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
What is the current status of trial NCT03451851?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2018-07-11. Estimated completion is 2026-12-18.
What conditions does trial NCT03451851 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03451851?
The interventions under investigation include: Guselkumab (DRUG), Etanercept (DRUG), Placebo for guselkumab (DRUG).
Who is sponsoring clinical trial NCT03451851?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03451851 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03451851's enrollment target sits among peer trials
120 54th of 125 higher than 71 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
-
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI